Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine — ACHIEVE II

Migraine, With or Without Aura Clinical Trial

Official title:
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Status Completed

Clinical Trial Summary

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02867709
Study type	Interventional
Source	Allergan
Contact
Status	Completed
Phase	Phase 3
Start date	August 26, 2016
Completion date	February 26, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02848326` - Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention	Phase 2/Phase 3
Completed	`NCT02873221` - An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine	Phase 3
Completed	`NCT03237845` - Safety and Efficacy in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT02828020` - Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine	Phase 3
Completed	`NCT03235479` - Safety and Efficacy Study in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT03461757` - Trial in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT03266588` - Open Label Safety Study in Acute Treatment of Migraine	Phase 2/Phase 3